Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Avalo Therapeutics, Inc. (AVTX) had Return on Equity of -16.52% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-13.72M |
|
-- |
|
-- |
|
$19.80M |
|
$-19.80M |
|
$6.15M |
|
$-13.59M |
|
$-13.59M |
|
$-13.72M |
|
$-13.72M |
|
$-13.72M |
|
$-13.72M |
|
$-19.74M |
|
$-19.79M |
|
13.40M |
|
13.40M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$105.29M |
|
$0.46M |
|
$11.17M |
|
$116.46M |
|
$12.94M |
|
-- |
|
$20.47M |
|
$33.41M |
|
$83.05M |
|
$72.55M |
|
$83.05M |
|
18.51M |
|
| Cash Flow Statement Financials | |
$-51.46M |
|
$-81.72M |
|
$14.59M |
|
$134.70M |
|
$16.11M |
|
$-118.59M |
|
$13.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-51.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-16.52% |
-18.91% |
|
-11.78% |
|
-16.52% |
|
$4.49 |
|
$-3.84 |
|
$-3.84 |
|